183 related articles for article (PubMed ID: 15615715)
1. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments.
Cole NB; Murphy DD; Lebowitz J; Di Noto L; Levine RL; Nussbaum RL
J Biol Chem; 2005 Mar; 280(10):9678-90. PubMed ID: 15615715
[TBL] [Abstract][Full Text] [Related]
2. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.
Uversky VN; Li J; Fink AL
J Biol Chem; 2001 Nov; 276(47):44284-96. PubMed ID: 11553618
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
Lashuel HA; Petre BM; Wall J; Simon M; Nowak RJ; Walz T; Lansbury PT
J Mol Biol; 2002 Oct; 322(5):1089-102. PubMed ID: 12367530
[TBL] [Abstract][Full Text] [Related]
4. Methionine oxidation, alpha-synuclein and Parkinson's disease.
Glaser CB; Yamin G; Uversky VN; Fink AL
Biochim Biophys Acta; 2005 Jan; 1703(2):157-69. PubMed ID: 15680224
[TBL] [Abstract][Full Text] [Related]
5. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications.
Norris EH; Giasson BI; Ischiropoulos H; Lee VM
J Biol Chem; 2003 Jul; 278(29):27230-40. PubMed ID: 12857790
[TBL] [Abstract][Full Text] [Related]
6. Lipid interaction of alpha-synuclein during the metal-catalyzed oxidation in the presence of Cu2+ and H2O2.
Lee EN; Lee SY; Lee D; Kim J; Paik SR
J Neurochem; 2003 Mar; 84(5):1128-42. PubMed ID: 12603836
[TBL] [Abstract][Full Text] [Related]
7. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?
Shtilerman MD; Ding TT; Lansbury PT
Biochemistry; 2002 Mar; 41(12):3855-60. PubMed ID: 11900526
[TBL] [Abstract][Full Text] [Related]
8. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.
Sharon R; Bar-Joseph I; Frosch MP; Walsh DM; Hamilton JA; Selkoe DJ
Neuron; 2003 Feb; 37(4):583-95. PubMed ID: 12597857
[TBL] [Abstract][Full Text] [Related]
9. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide.
Paik SR; Shin HJ; Lee JH
Arch Biochem Biophys; 2000 Jun; 378(2):269-77. PubMed ID: 10860544
[TBL] [Abstract][Full Text] [Related]
10. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.
Ding TT; Lee SJ; Rochet JC; Lansbury PT
Biochemistry; 2002 Aug; 41(32):10209-17. PubMed ID: 12162735
[TBL] [Abstract][Full Text] [Related]
11. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
12. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
Rochet JC; Outeiro TF; Conway KA; Ding TT; Volles MJ; Lashuel HA; Bieganski RM; Lindquist SL; Lansbury PT
J Mol Neurosci; 2004; 23(1-2):23-34. PubMed ID: 15126689
[TBL] [Abstract][Full Text] [Related]
13. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.
Cole NB; Murphy DD; Grider T; Rueter S; Brasaemle D; Nussbaum RL
J Biol Chem; 2002 Feb; 277(8):6344-52. PubMed ID: 11744721
[TBL] [Abstract][Full Text] [Related]
14. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation.
Zhu M; Li J; Fink AL
J Biol Chem; 2003 Oct; 278(41):40186-97. PubMed ID: 12885775
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein oligomerization: a role for lipids?
Welch K; Yuan J
Trends Neurosci; 2003 Oct; 26(10):517-9. PubMed ID: 14522142
[TBL] [Abstract][Full Text] [Related]
16. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
18. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
Conway KA; Rochet JC; Bieganski RM; Lansbury PT
Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929
[TBL] [Abstract][Full Text] [Related]
19. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders.
Norris EH; Giasson BI
Antioxid Redox Signal; 2005; 7(5-6):672-84. PubMed ID: 15890012
[TBL] [Abstract][Full Text] [Related]
20. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
Uversky VN; Li J; Souillac P; Millett IS; Doniach S; Jakes R; Goedert M; Fink AL
J Biol Chem; 2002 Apr; 277(14):11970-8. PubMed ID: 11812782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
